Yunnan Botanee Bio-Technology GroupLTD Future Growth
Future criteria checks 4/6
Yunnan Botanee Bio-Technology GroupLTD is forecast to grow earnings and revenue by 32.4% and 14.4% per annum respectively. EPS is expected to grow by 32% per annum. Return on equity is forecast to be 15.3% in 3 years.
Key information
32.4%
Earnings growth rate
32.0%
EPS growth rate
| Personal Products earnings growth | 25.5% |
| Revenue growth rate | 14.4% |
| Future return on equity | 15.3% |
| Analyst coverage | Good |
| Last updated | 22 Nov 2024 |
Recent future growth updates
Recent updates
Earnings Troubles May Signal Larger Issues for Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Shareholders
Nov 02
Is Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) Trading At A 39% Discount?
Oct 19The Market Lifts Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957) Shares 26% But It Can Do More
Sep 27Is Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) A Risky Investment?
Sep 25Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Will Pay A Smaller Dividend Than Last Year
Jun 03A Look At The Fair Value Of Yunnan Botanee Bio-Technology Group Co.LTD (SZSE:300957)
May 24Yunnan Botanee Bio-Technology GroupLTD's (SZSE:300957) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 02Yunnan Botanee Bio-Technology GroupLTD (SZSE:300957) Has A Pretty Healthy Balance Sheet
Feb 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 8,471 | 1,241 | 1,146 | 1,383 | 21 |
| 12/31/2025 | 7,613 | 1,111 | 954 | 1,077 | 23 |
| 12/31/2024 | 6,567 | 713 | 1,432 | 894 | 20 |
| 9/30/2024 | 6,108 | 592 | 117 | 492 | N/A |
| 6/30/2024 | 5,959 | 791 | 120 | 467 | N/A |
| 3/31/2024 | 5,756 | 775 | 342 | 649 | N/A |
| 12/31/2023 | 5,522 | 757 | 336 | 610 | N/A |
| 9/30/2023 | 5,550 | 1,113 | 554 | 808 | N/A |
| 6/30/2023 | 5,332 | 1,106 | 550 | 843 | N/A |
| 3/31/2023 | 5,069 | 1,064 | 434 | 740 | N/A |
| 1/1/2023 | 5,014 | 1,051 | 416 | 769 | N/A |
| 9/30/2022 | 4,805 | 1,025 | 532 | 891 | N/A |
| 6/30/2022 | 4,660 | 993 | 637 | 999 | N/A |
| 3/31/2022 | 4,323 | 930 | 601 | 935 | N/A |
| 1/1/2022 | 4,022 | 863 | 882 | 1,153 | N/A |
| 9/30/2021 | 3,332 | 683 | 518 | 721 | N/A |
| 6/30/2021 | 3,107 | 648 | 570 | 702 | N/A |
| 3/31/2021 | 2,825 | 568 | 438 | 546 | N/A |
| 12/31/2020 | 2,636 | 544 | 342 | 431 | N/A |
| 12/31/2019 | 1,944 | 412 | 454 | 515 | N/A |
| 12/31/2018 | 1,240 | 261 | 71 | 102 | N/A |
| 12/31/2017 | 798 | 154 | N/A | 202 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300957's forecast earnings growth (32.4% per year) is above the savings rate (2.8%).
Earnings vs Market: 300957's earnings (32.4% per year) are forecast to grow faster than the CN market (26.3% per year).
High Growth Earnings: 300957's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300957's revenue (14.4% per year) is forecast to grow faster than the CN market (13.9% per year).
High Growth Revenue: 300957's revenue (14.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300957's Return on Equity is forecast to be low in 3 years time (15.3%).